84110-34-9

Basic information

• Product Name: 2-Methylpropaneboronic acid (1S,2S,3R,5S)-(+)-2,3-pinanediol ester
• Synonyms: 2-Methylpropaneboronic acid (1S,2S,3R,5S)-(+)-2,3-pinanediol ester;(3aS,4S,6S,7aR)-2-Isobutyl-3a,5,5-triMethylhexahydro-4,6-Methanobenzo[d][1,3,2]dioxaborole;(2-Methyl propyl) boronic acid (1S,2S,3R,5S ) -(+) -2,3-pinanediol ester;2-Methylpropaneboronic acid (1S,2S,3R,5S)-(+)-2,3-pinanediol ester (3aS,4S,6S,7aR)-2-Isobutyl-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborole;(3aS,4S,6S,7aR)-2-Isobutyl-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborole;(3aS,4S,6S,7aR);-2-Isobutyl-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborole;4,6-Methano-1,3,2-benzodioxaborole, hexahydro-3a,5,5-trimethyl-2-(2-methylpropyl)-, (3aS,4S,6S,7aR)-
• CAS NO: 84110-34-9
• Molecular Formula: C₁₄H₂₅BO₂
• Molecular Weight: 236.17
• Mol File: 84110-34-9.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 272.3±9.0℃ (760 Torr)
• Flash Point: 118.5±18.7℃
• Appearance: /
• Density: 0.97±0.1 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 2-Methylpropaneboronic acid (1S,2S,3R,5S)-(+)-2,3-pinanediol ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methylpropaneboronic acid (1S,2S,3R,5S)-(+)-2,3-pinanediol ester(84110-34-9)
• EPA Substance Registry System: 2-Methylpropaneboronic acid (1S,2S,3R,5S)-(+)-2,3-pinanediol ester(84110-34-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37
• TSCA: No
• Hazardous Substances Data: 84110-34-9(Hazardous Substances Data)

Usage

Uses

suzuki reaction

Upstream product

• 18680-27-8 pinanediol 
• 67562-20-3 2-isobutyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 593-71-5 Chloroiodomethane 
• 90084-26-7 (3aS,4S,6S,7aR)-2-isopropyl-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborole 
• 926-62-5 isobutylmagnesium bromide 
• 819816-59-6 (3aS,4s,6S,7aR)-hexahydro-3a,5,5-trimethyl-2-(1-methylethoxy)-4,6-methano-1,3,2-benzodioxaborole 
• 7785-70-8 (+)-α-pinene 
• 84110-40-7 Dihydroxy-isobutyl-boran 
• 57022-61-4 (+)-pinanediol 

Downstream Products

• 1201903-02-7 2,5-dichloro-N-[2-({(1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexa-hydro-2H-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}amino)-2-oxoethyl]benzamide 
• 205393-22-2 N-[(1S)-1[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]carbonyl]-2-benzyl]2-pyrazine carboxamide 
• 1310383-72-2 (aR,3aS,4S,6S,7aR)-hexahydro-3a,8,8-trimethyl-α-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate 
• 779357-85-6 (1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxabor-ol-2-yl]butan-1-amine hydrochloride 
• 179324-86-8 (1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^2,6]decan-4-yl]butan-1-amine 

Relevant articles and documents

Synthesis of four isotopically labeled forms of a proteasome inhibitor, bortezomib

[D2](1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]-amino]butyl] boronic acid ([D2]bortezomib), a proteasome inhibitor, was synthesized in 11 steps from isobutyryl chloride. Key steps in the synthesis inclu

SUBSTITUTED BORIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND APPLICATION THEREOF

A substituted boric acid compound, a pharmaceutical composition comprising same, and an application thereof. The substituted boric acid compound is a compound represented by formula (I), or a crystal form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The boric acid compound has proteasome inhibitory activity, good pharmacodynamic/pharmacokinetic performance, good applicability, and high safety, and can be used for preparing drugs for treating diseases related to proteasomes.

De Novo Design of Boron-Based Peptidomimetics as Potent Inhibitors of Human ClpP in the Presence of Human ClpX

Boronic acids have attracted the attention of synthetic and medicinal chemists due to boron's ability to modulate enzyme function. Recently, we demonstrated that boron-containing amphoteric building blocks facilitate the discovery of bioactive aminoboronic acids. Herein, we have augmented this capability with a de novo library design and a virtual screening platform modified for covalent ligands. This technique has allowed us to rapidly design and identify a series of α-aminoboronic acids as the first inhibitors of human ClpXP, which is responsible for the degradation of misfolded proteins.